Loading
Life sciences · Journal article
Microorganisms · September 5, 2026
Early or partial results. Treat as a signal, not a conclusion.
This experimental study in mice demonstrates that lactational enrofloxacin exposure is associated with persistent fat accumulation, dyslipidemia, and gut dysbiosis, mediated via a putative gut microbiota–lipopolysaccharide–PPARγ signaling pathway. Microbiota depletion reversed metabolic abnormalities, supporting a causal role for dysbiosis. The findings are mechanistically coherent but remain preliminary, lacking human validation or definitive proof of the proposed TLR4–PPARγ mechanism.
Experimental animal model study with in vitro cell culture mechanistic investigation. Neonatal and postnatal mouse offspring exposed to enrofloxacin via maternal lactation; 3T3-L1 preadipocyte cell line.. Intervention: Lactational enrofloxacin exposure; microbiota depletion via antibiotic cocktail; LPS treatment in vitro. Compared with: Control offspring (no enrofloxacin); untreated 3T3-L1 cells; pharmacological PPARγ/TLR4 inhibition.
Lactational enrofloxacin exposure associated with persistent weight gain, fat accumulation, and progressive dyslipidemia in offspring Adipose expansion attributed to adipocyte hyperplasia (not hypertrophy alone) Exposure triggered sustained gut dysbiosis with increased Gram-negative Proteobacteria and elevated circulating LPS levels
TLR4 and PPARγ involvement described as 'putative'; pharmacological inhibition data not detailed in abstract
These findings suggest early-life fluoroquinolone exposure may carry long-term metabolic risks in humans via microbiota disruption, but animal data alone cannot guide clinical practice. Human observational or intervention studies are needed to establish clinical relevance and support prevention strategies.
A mechanistic study in mouse models with in vitro validation, demonstrating a plausible pathway but lacking human data, clinical hard endpoints, or definitive proof of causation in the proposed mechanism.
As stated by the source record.
Quoted from the source exactly as published.
These findings suggest early-life fluoroquinolone exposure may carry long-term metabolic risks in humans via microbiota disruption, but animal data alone cannot guide clinical practice. Human observational or intervention studies are needed to establish clinical relevance and support prevention strategies.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
Early-life antibiotic exposure is a critical environmental trigger for developmental metabolic disorders and long-term obesity risk. Lactational enrofloxacin exposure exerts potential metabolic programming toxicity, but its long-term effects and underlying mechanisms remain poorly defined. This study aimed to investigate the persistent influences of lactational enrofloxacin exposure on postnatal growth, lipid metabolism and adipogenesis in mouse offspring and explore the potential gut microbiota-associated regulatory mechanism. A combined in vivo and in vitro approach was utilized. In vivo mouse models with lactational enrofloxacin exposure were established to assess growth phenotypes, serum lipid profiles, adipose morphology, and gut microbial composition via high-throughput sequencing. Antibiotic cocktail treatment was performed to deplete gut microbiota. In vitro 3T3-L1 cell models and pharmacological inhibition assays were used to investigate the downstream signaling pathway. Lactational enrofloxacin exposure was associated with disrupted postnatal growth, persistent weight gain, fat accumulation and progressive dyslipidemia in offspring. Adipose expansion was mainly attributed to adipocyte hyperplasia. It triggered sustained gut dysbiosis, increased Gram-negative Proteobacteria, and elevated circulating lipopolysaccharide (LPS) levels (systemic endotoxemia). Microbiota depletion largely reversed these metabolic abnormalities. In vitro, LPS facilitated preadipocyte differentiation and lipid deposition, consistent with activation of a PPARγ-dependent mechanism (putatively via TLR4). Our findings suggest that lactational enrofloxacin exposure is associated with persistent fat accumulation and lipid metabolism disorders in offspring and support a key role for the gut microbiota–LPS–PPARγ signaling pathway, with TLR4 as the putative upstream receptor, in this process. These findings provide insights into the developmental metabolic toxicity of early-life fluoroquinolone exposure and offer a theoretical basis for preventing early-onset metabolic diseases.
Taken from the source record, never inferred. Follow any of these and new work involving them reaches your briefing.